Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948

By Sabela Ojea

Nurix Therapeutics said the Food and Drug Administration has granted fast-track designation for NX-5948, its treatment for certain types of lymphocytic cancer.

NX-5948 is a degrader of Bruton's tyrosine kinase and is being studied to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The clinical-stage biopharmaceutical company on Tuesday said the designation follows encouraging safety and efficacy data from its ongoing Phase 1 clinical trial.

The FDA's fast-track designation is aimed at facilitating and expediting the development and review of drug candidates.

Write to Sabela Ojea at [e-mail]; @sabelaojeaguix

(END) Dow Jones Newswires

01-16-24 1633ET